



(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 47/36 (2006.01)  
A61K 9/10 (2006.01) A61K 47/38 (2006.01)  
A61K 31/44 (2006.01) A61P 43/00 (2006.01)  
A61K 47/32 (2006.01) B05B 11/00 (2023.01)

(21) International Application Number:

PCT/EP2024/077436

(22) International Filing Date:

30 September 2024 (30.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/586,254 28 September 2023 (28.09.2023) US  
2315863.7 17 October 2023 (17.10.2023) GB  
63/599,900 16 November 2023 (16.11.2023) US

(71) Applicant: **MOSANNA THERAPEUTICS AG**  
[CH/CH]; Grellingerstrasse 91, 4052 Basel (CH).

(72) Inventors: **BROWN, Marc Barry**; c/o Mosanna Therapeutics AG, Grellingerstrasse 91, 4052 Basel (CH). **HILL, Paul Michael David**; c/o Mosanna Therapeutics AG,

Grellingerstrasse 91, 4052 Basel (CH). **ALLY, Alisha Taya**; c/o Mosanna Therapeutics AG, Grellingerstrasse 91, 4052 Basel (CH). **EVANS, Charles Rodey Greenaway**; c/o Mosanna Therapeutics AG, Grellingerstrasse 91, 4052 Basel (CH). **TALBOT, Jonathan Peter**; c/o Mosanna Therapeutics AG, Grellingerstrasse 91, 4052 Basel (CH). **JANSSENS, Sandrien**; c/o Mosanna Therapeutics AG, Grellingerstrasse 91, 4052 Basel (CH).

(74) Agent: **J A KEMP LLP**; 80 Turnmill Street, London Greater London EC1M 5QU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA




FIG. 1

(57) **Abstract:** The present disclosure relates to nasal pharmaceutical compositions for the treatment of obstructive sleep apnea, drug-device combinations for intranasal delivery of the pharmaceutical compositions, and methods of treatment.

[Continued on next page]

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*